Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
MYO vs NPCE: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
NPCE Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 8–2 Matrix Metrics)
NPCE Overall Winner
6-Pillar Tally: MYO 1 – 4 NPCE (1 Tie)
Matrix Metrics: MYO 2 – 8 NPCE
As of Nov 20, 2026, Neuropace, Inc. (NPCE) is the stronger overall head-to-head candidate over Myomo Inc. (MYO) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MYO carries a Unified Composite Score of 40.1/100 (SELL) at $0.81 (N/M Forward P/E, -21.8% operating margin), whereas NPCE carries 54.4/100 (HOLD) at $7.95 (91.7x Forward P/E, -9.6% operating margin).
- Growth vs. Quality Trade-Off: NPCE earns the overall head-to-head edge with a stronger Unified Composite Score (54.4/100 HOLD vs. MYO 40.1/100 SELL) and 1.17β · 135% Vol risk profile, whereas MYO leads top-line expansion (+22.2% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
- Technical & Structure Timing Caution: MYO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.7); meanwhile NPCE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 25.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About MYO vs NPCE
MYO
Myomo Inc.
$0.81
-3.45% 1D
Market Cap
$33.7M
TTM Revenue
$46M
Forward P/E
N/M
Beta / 30D Vol
2.22β · 107% Vol
Unified Composite Score
40.1
SELL
Tech 25.0
Fund 43.0
Flow 58.0
Mom 59.0
Weinstein Technical Phase
Markdown · Sell / avoid
NPCE
Head-to-Head Winner
Neuropace, Inc. Common Stock
$7.95
-2.33% 1D
Market Cap
$280.4M
TTM Revenue
$107M
Forward P/E
91.7x
Beta / 30D Vol
1.17β · 135% Vol
Unified Composite Score
54.4
HOLD
Tech 55.0
Fund 61.0
Flow 67.0
Mom 73.9
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (MYO 1 – 4 NPCE)
1. Valuation Multiples
NPCE
Forward P/E
N/M
91.7x
Trailing P/E
N/M
91.7x
PEG Ratio
N/M
N/M
EV / Revenue
0.9x
3.2x
2. Growth & Scale
NPCE
Revenue Growth (YoY)
+22.2%
-1.1%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$46M
$107M
Market Cap
$33.7M
$280.4M
3. Profitability & Quality
NPCE
Gross Margin
70.1%
77.8%
Operating Margin
-21.8%
-9.6%
Net Profit Margin
-33.1%
-17.7%
Return on Equity (ROE)
-173.5%
-97.0%
4. Balance Sheet & Cash Flow
NPCE
Cash Generation (TTM)
-$9.1M
-$12M
Cash Flow Margin
-20.0%
-11.6%
Net Cash / Leverage
$8.9M Net Debt (3.44x D/E)
$59M Net Debt (6.05x D/E)
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
MYO
Options Structure Phase
UNCLASSIFIED
BREAKDOWN
Current IV / %ile
266.0% (81st %ile)
59.9% (10th %ile)
Put/Call OI Skew
N/A
0.38x (Call-Skewed)
OBV Trend / Tech Phase
NEUTRAL · Markdown
DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Medical Devices Operator
Medical Devices Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: MYO (2) vs NPCE (8)| Institutional Metric | MYO | NPCE | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $33.7M | $280.4M | NPCE | |
| Trailing P/E Ratio | N/M | 91.7x | NPCE | |
| Forward P/E Ratio | N/M | 91.7x | NPCE | |
| Revenue Growth (YoY) | +22.2% | -1.1% | MYO | |
| Operating Margin (TTM) | -21.8% | -9.6% | NPCE | |
| Net Profit Margin | -33.1% | -17.7% | NPCE | |
| Return on Equity (ROE) | -173.5% | -97.0% | NPCE | |
| 52-Week Range Position | 16% ($1–$2) | 18% ($5–$20) | NPCE | |
| Beta / 30D Volatility | 2.22β · 107% Vol | 1.17β · 135% Vol | MYO | |
| Unified Institutional Score | 40.1 / 100 (SELL) | 54.4 / 100 (HOLD) | NPCE | |
| Trailing 12M Revenue (USD) | $46M | $107M | Scale | |
| Gross Profit Margin (TTM) | 70.1% | 77.8% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 0.9x EV/Rev | N/M PEG · 3.2x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$9.1M ($8.9M Net Debt (3.44x D/E)) | -$12M ($59M Net Debt (6.05x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
MYO +5.98 pp
3M Horizon
MYO +1.52 pp
6M Horizon
MYO +30.99 pp
1Y Horizon
MYO +55.92 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | MYO Revenue | NPCE Revenue | MYO Op. Margin | NPCE Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $0M | N/A | -430.8% | N/A | MYO |
| FY2019 | $0M | N/A | -281.3% | N/A | MYO |
| FY2020 | $10M | $40M | -138.5% | -31.7% | NPCE |
| FY2021 | $10M | $50M | -74.1% | -52.5% | NPCE |
| FY2022 | $20M | $50M | -68.6% | -89.6% | MYO |
| FY2023 | $20M | $70M | -42.8% | -41.5% | NPCE |
| FY2024 | $30M | $80M | -19.1% | -27.1% | MYO |
| FY2025 | $40M | $100M | -35.2% | -16.3% | NPCE |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
MYO
UNCLASSIFIED
Current IV
266.0%
IV Percentile
81st %ile
Put/Call OI Skew
N/A
IV Regime
Extreme (>80th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact MYO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
NPCE
BREAKDOWN
Current IV
59.9%
IV Percentile
10th %ile
Put/Call OI Skew
0.38x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
Exact NPCE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
MYO Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
NPCE Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ MYO vs NPCE Key Questions & Quantitative Answers
As of Nov 20, 2026, Neuropace, Inc. (NPCE) is the stronger overall head-to-head candidate over Myomo Inc. (MYO) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MYO carries a Unified Composite Score of 40.1/100 (SELL) at $0.81 (N/M Forward P/E, -21.8% operating margin), whereas NPCE carries 54.4/100 (HOLD) at $7.95 (91.7x Forward P/E, -9.6% operating margin). Growth vs. Quality Trade-Off: NPCE earns the overall head-to-head edge with a stronger Unified Composite Score (54.4/100 HOLD vs. MYO 40.1/100 SELL) and 1.17β · 135% Vol risk profile, whereas MYO leads top-line expansion (+22.2% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: MYO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.7); meanwhile NPCE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 25.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
NPCE leads the Growth & Scale pillar: MYO posts +22.2% YoY revenue growth and +0.0% YoY earnings growth on $46M TTM revenue (70.1% gross margin, -21.8% operating margin), compared with NPCE at -1.1% YoY revenue growth and +0.0% YoY earnings growth on $107M TTM revenue (77.8% gross margin, -9.6% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), MYO cumulative revenue shifted +300.0% while NPCE shifted +150.0%. In operating R&D and SG&A reinvestment, MYO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NPCE.
NPCE screens cheaper on headline valuation multiples. MYO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.9x EV/Revenue (-20.0% FCF margin), whereas NPCE trades at 91.7x Forward P/E, 91.7x Trailing P/E, N/M PEG, and 3.2x EV/Revenue (-11.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MYO (-173.5% ROE) versus NPCE (-97.0% ROE) capital efficiency.
In options market volatility and institutional positioning, MYO carries 266.0% implied volatility (81st %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.22β · 107% Vol realized risk). By comparison, NPCE carries 59.9% implied volatility (10th %ile, Compressed (<25th %ile)), a 0.38x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.17β · 135% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
NPCE vs MYO · Reverse Pair
NPCE vs TMCI
· Sector Peer
NPCE vs SGHT
· Sector Peer
NPCE vs BVS
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking